Intra-Cellular Says Phase3 Trial Study 502 Of Lumateperone In MDD Meets Primary Endpoint

Biopharmaceutical company Intra-Cellular Therapies, Inc. (ITCI) announced Tuesday positive topline results from Study 502 evaluating lumateperone 42 mg as an adjunctive therapy to antidepressants for the treatment of Major Depressive Disorder (MDD). This trial, in conjunction with the previously reported positive Phase 3 study, Study 501, forms the basis for lumateperone sNDA for the adjunctive...

Read More

Dollar Loses Ground Against Major Counterparts

The U.S. dollar drifted lower against its major counterparts on Thursday after data showing a much bigger than expected increase in U.S. jobless claims added to recently renewed optimism that the Federal Reserve will lower interest rates in the coming months. The report said initial jobless claims climbed to 231,000, an increase of 22,000 from...

Read More

Pound Lower Against Majors

The pound traded lower on Wednesday, amid a resurgence in the U.S. dollar ahead of key inflation data. Personal consumption expenditures price index, scheduled for release on Thursday, may influence investor expectations about the Fed\'s potential moves on interest rates. On Tuesday, Fed Governor Michelle Bowman said inflation will continue to decline further but it\'s...

Read More

Thai Stock Market Due For Support On Tuesday

The Thai stock market has moved lower in three straight sessions, slipping more than 20 points or 1.5 percent along the way. The Stock Exchange of Thailand now rests just beneath the 1,300-point plateau although it may stop the bleeding on Tuesday. The global forecast for the Asian markets suggests little movement ahead of key...

Read More